Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03740685
Recruitment Status : Not yet recruiting
First Posted : November 14, 2018
Last Update Posted : November 14, 2018
Sponsor:
Information provided by (Responsible Party):
Mahmoud Abdelhamed, Assiut University

Brief Summary:
changes in high sensitive C reactive protien with different treatment modalities in acute pancreatitis

Condition or disease Intervention/treatment
Pancreatitis, Acute Diagnostic Test: High sesitive C reactive protien

Layout table for study information
Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis
Estimated Study Start Date : November 9, 2018
Estimated Primary Completion Date : November 9, 2018
Estimated Study Completion Date : October 8, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis

Group/Cohort Intervention/treatment
Patients with acute pancreatitis
All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
Diagnostic Test: High sesitive C reactive protien
High sesitive C reactive protien will be evaluated at admission time and after 36 hours




Primary Outcome Measures :
  1. High sesitive C reactive protien [ Time Frame: 72hours ]
    Level of High sesitive C reactive protien expected to be changed with different lines of treatment and will be compaered

  2. Serum Amylase [ Time Frame: 72hours ]
    Level of Serum Amylase expected to be changed with different lines of treatment and will be compaered

  3. Serum Lipase [ Time Frame: 72hours ]
    Level of Serum Lipase expected to be changed with different lines of treatment and will be compaered



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with acute pancreatitis
Criteria

Inclusion Criteria:

  • Age>=18 years
  • Diagnosis of acute pancreatitis confirmed by at least 2 of the following:

    1. Typical epigastric abdominal pain
    2. Elevation amylase/lipase >3 times upper limit normal and/or
    3. Confirmatory findings on cross-sectional imaging
    4. Enrollment within 8 hours of presentation

Exclusion Criteria:

  • Class II or greater NYHA heart failure
  • Oxygen dependent COPD
  • Chronic kidney disease>stage 2
  • Existing necrosis on abdominal CT
  • Organ dysfunction prior to enrollment
  • Sepsis
  • Acute respiratory distress syndrome
  • Malignancy not in remission for at least 5 years
  • Active drug use
  • Known allergy to dexamethasone
  • Altered mental status
  • Insulin-requiring diabetes
  • Abdominal surgery within 60days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03740685


Contacts
Layout table for location contacts
Contact: mahmoud Abd Elhamed, principal participant 01017141345 mahmoudsisi100@yahoo.com

Locations
Layout table for location information
Egypt
Assiut University
Assuit, Egypt, 171516
Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Mahmoud Abdelhamed, principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03740685     History of Changes
Other Study ID Numbers: CHCPWDTM
First Posted: November 14, 2018    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis
Pancreatic Diseases
Digestive System Diseases